Experts discussed the integration of GLP-1 agonists and lifestyle interventions to mitigate obesity-related cancer risks and improve long-term survival.
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.